From DNA to Doses: How Pharmacogenomics Transforms Depression Care in Community Pharmacy?

Abstract

Pharmacogenomic testing can identify these genetic variations, allowing healthcare providers to adjust drug selection and dosage accordingly. These tests typically involve a simple cheek swab or saliva sample, which is then analysed to identify specific genetic variations that affect drug metabolism and response. Cytochrome P450 (CYP450) enzyme is responsible for the metabolism of many antidepressants. CYP2D6 and CYP2C19 can lead to differences in drug metabolism. serotonin transporter gene (SLC6A4), which influences the reuptake of serotonin, a neurotransmitter plays a role in mood regulation. Brain-Derived Neurotrophic Factor (BDNF) gene, known as Val66Met, has been linked to differences in response to antidepressants. Effective implementation of pharmacogenomics in clinical practice requires supportive policies that address issues such as reimbursement, education, and privacy. The pharmacist’s responsibilities include interpreting genetic data, collaborating with healthcare providers, counselling patients, and integrating pharmacogenomics into medication therapy management. By identifying and focusing on the patients with predicted gene-drug interactions, use of a combinatorial pharmacogenomic test significantly improved outcomes among patients with major depression disorder. Personalized medicine should take advantage of an informational structured framework of genetic, phenotypic and environmental factors to provide the healthcare system with useful tools that can optimize the effectiveness of specific treatment.